Ning Liu1, Kimberly J Johnson2, Cynthia X Ma3. 1. Washington University Brown School of Public Health, St. Louis, MO. 2. Washington University Brown School of Public Health, St. Louis, MO; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO. 3. Washington University Brown School of Public Health, St. Louis, MO; Section of Medical Oncology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address: cynthiaxma@wustl.edu.
Abstract
BACKGROUND: Male breast cancer is rare and understudied compared with female breast cancer. A current comparison with female breast cancer could assist in bridging this gap. Although conflicting data have been reported on male and female survival outcomes, data from 1973 through 2005 in the Surveillance, Epidemiology, and End Results (SEER) program have demonstrated that the improvement in breast cancer survival in men has fallen behind that of women. As treatment for breast cancer has improved significantly, an updated analysis using a contemporary population is necessary. MATERIALS AND METHODS: An analysis of SEER data from patients with a diagnosis of primary breast cancer from 2005 to 2010 were included. A Cox regression model was used to examine the association between sex and breast cancer mortality after controlling for prognostic factors, including age, race, marital status, disease stage, estrogen and progesterone receptor status, lymph node involvement, tumor grade, surgery, and geography. Subgroup analyses were performed by race and stage. RESULTS: We included a total of 289,673 breast cancer cases (2054 men) with a diagnosis from 2005 to 2010. The 5-year survival rate for male patients was lower than that for female patients (82.8% vs. 88.5%). After controlling for other factors, the risk of death in men was 43% greater than that in women during the follow-up period (hazard ratio, 1.43; 95% confidence interval, 1.26-1.61). Similar results were noted in the race and stage subgroup analyses. CONCLUSION: In recent years, male breast cancer patients have had worse survival outcomes compared with those of female patients.
BACKGROUND:Male breast cancer is rare and understudied compared with female breast cancer. A current comparison with female breast cancer could assist in bridging this gap. Although conflicting data have been reported on male and female survival outcomes, data from 1973 through 2005 in the Surveillance, Epidemiology, and End Results (SEER) program have demonstrated that the improvement in breast cancer survival in men has fallen behind that of women. As treatment for breast cancer has improved significantly, an updated analysis using a contemporary population is necessary. MATERIALS AND METHODS: An analysis of SEER data from patients with a diagnosis of primary breast cancer from 2005 to 2010 were included. A Cox regression model was used to examine the association between sex and breast cancer mortality after controlling for prognostic factors, including age, race, marital status, disease stage, estrogen and progesterone receptor status, lymph node involvement, tumor grade, surgery, and geography. Subgroup analyses were performed by race and stage. RESULTS: We included a total of 289,673 breast cancer cases (2054 men) with a diagnosis from 2005 to 2010. The 5-year survival rate for male patients was lower than that for female patients (82.8% vs. 88.5%). After controlling for other factors, the risk of death in men was 43% greater than that in women during the follow-up period (hazard ratio, 1.43; 95% confidence interval, 1.26-1.61). Similar results were noted in the race and stage subgroup analyses. CONCLUSION: In recent years, male breast cancerpatients have had worse survival outcomes compared with those of female patients.
Authors: Jennifer K Plichta; Yi Ren; Caitlin E Marks; Samantha M Thomas; Rachel A Greenup; Laura H Rosenberger; Oluwadamilola M Fayanju; Susan G R McDuff; E Shelley Hwang; Jeremy Force Journal: Ann Surg Oncol Date: 2020-07-23 Impact factor: 5.344
Authors: Eleni Zografos; Stavros C Proikakis; Athanasios K Anagnostopoulos; Anna-Maria Korakiti; Flora Zagouri; Maria Gazouli; George T Tsangaris Journal: Cancer Genomics Proteomics Date: 2022 Mar-Apr Impact factor: 4.069
Authors: Mariam F Eskander; Yaming Li; Oindrila Bhattacharyya; Allan Tsung; Bridget A Oppong; Ahmad Hamad; Margaret Gatti-Mays; Samilia Obeng-Gyasi Journal: Breast Cancer Res Treat Date: 2021-08-12 Impact factor: 4.624
Authors: Siddhartha Yadav; Dhauna Karam; Irbaz Bin Riaz; Hao Xie; Urshila Durani; Narjust Duma; Karthik V Giridhar; Tina J Hieken; Judy C Boughey; Robert W Mutter; John R Hawse; Rafael E Jimenez; Fergus J Couch; Roberto A Leon-Ferre; Kathryn J Ruddy Journal: Cancer Date: 2019-10-07 Impact factor: 6.860
Authors: Ryan W Woods; Lonie R Salkowski; Mai Elezaby; Elizabeth S Burnside; Roberta M Strigel; Amy M Fowler Journal: Clin Imaging Date: 2019-11-28 Impact factor: 1.605
Authors: Yunan Han; Justin Xavier Moore; Marvin Langston; Lindsay Fuzzell; Saira Khan; Marquita W Lewis; Graham A Colditz; Ying Liu Journal: Cancer Causes Control Date: 2019-08-27 Impact factor: 2.506